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Abstract
Background: Neoplasms of the mammary gland are among the most common diseases in female domestic dogs
(Canis familiaris). It is assumed that reproductive hormones influence tumorigenesis in this species, although the
precise role of the endocrine milieu and reproductive state is subject to continuing discussion. In line with this, a
recent systematic review of available data on the development of mammary neoplasms revealed weak evidence for
risk reduction after neutering and an effect of age at neutering. Investigation of several hormone receptors has
revealed decreased expression of estrogen receptor-alpha (ERα, ESR1), progesterone (P4) receptor (PGR), prolactin
(PRL) receptor (PRLR) and growth hormone receptor (GHR) associated with neoplastic differentiation of mammary
tissues. In other studies, increased levels of estrogens, progesterone and prolactin were found in serum and/or
tissue homogenates of dogs with malignant neoplasms. However, the association between these entities within
one animal population was never previously examined. Therefore, this study investigated the association between
circulating serum concentrations of estradiol-17β, progesterone and prolactin, and gene expression of ERα (ESR1),
ERβ (ESR2), PGR, PRLR, PRL and GHR, with respect to reproductive state (spayed vs. intact) and cycle stage (anestrus
vs. diestrus). Additionally, the expression of E-cadherin (CDH-1) was evaluated as a possible indicator of metastatic
potential.
Results: For all receptors, the lowest gene expression was found in malignant tumors compared to normal tissues
of affected dogs. Steroid levels were not influenced by their corresponding receptor expression in mammary
neoplasms, but increased PRL levels were negatively associated with low PRLR gene expression in malignant
tumors. The expression of CDH-1 was influenced by tumor malignancy and cycle stage, i.e., the highest gene
expression was found in benign mammary tumors in diestrous dogs compared to normal and malignant mammary
tissues of anestrous and spayed dogs.
Conclusions: Herein, it has been confirmed that transformation towards malignant neoplasms is associated with
significant reduction of gene expression of particular hormone receptors. Only PRLR in malignant tumors seems to
be influenced by circulating PRL levels. In dogs, CDH-1 can be used as a prognostic factor; its expression, however,
in benign tumors is influenced by cycle stage.
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Background
Estrogens (estradiol 17β; E2), progesterone (P4), prolactin
(PRL) and growth hormone (GH) are essential for physio-
logical mammary growth and development, which not
only take place during pregnancy but also occur with
every reproductive cycle. While estrogens induce ductal
growth, P4 is essential together with PRL for lengthening
and tertiary branching of the ductal system and stimula-
tion of lobulo-alveolar development [1, 2]. Furthermore,
PRL promotes changes of the alveolar cells towards a
secretory type and induces lactation [1–4]. The effects of
these hormones are mediated through binding to their
respective receptors within the mammary gland. Changes
in the expression of E2, P4 and GH receptors (ER, PGR
and GHR, respectively) but not of prolactin receptors
(PRLR) have been described in normal canine mammary
tissue during different phases of the estrous cycle [5–8].
In addition to physiological changes in the mammary
gland during the estrous cycle, different pathological
changes may occur. Tumors are considered to be the most
common disorders of the mammary gland in dogs. Repro-
ductive state and the endocrine milieu seem to play a
pivotal role in the development of canine mammary
tumors (CMT). The sparing effect of early spaying on
CMT formation has been known since the work of
Schneider and colleagues in 1969 [9]. However, a recent
systematic review of peer-reviewed journal articles con-
cluded that the evidence for a reduced CMT risk following
ovariohysterectomy, as well as for an influence of age at
neutering, is weak [10]. Studies investigating the impact of
spaying, performed concurrently or shortly before the
time of mammary tumor surgery, on disease-free interval
or survival time yielded inconsistent results, showing
either a beneficial effect of ovariohysterectomy or no effect
[11–15]. Yet, a role for E2 in mammary tumorigenesis was
suggested by its higher blood levels in dogs with malignant
neoplasms compared to those without tumors [16–18]. On
the other hand, bitches with inflammatory mammary
carcinoma had lower estrogen levels compared to animals
with other carcinoma subtypes [16]. An involvement of P4
in mammary tumorigenesis was also suggested, because
treatment with progestins increased the risk of CMT
[19–21], which is probably due to up-regulation of local
GH production within the gland [22]. However, no signifi-
cant differences in endogenously derived P4 serum con-
centrations were found between bitches with and without
mammary neoplasms [17, 18]. A tumorigenic effect of
PRL on the mammary tissue was hypothesized, because
dogs with CMT had higher PRL levels than healthy
animals [17, 23].
Despite the presumed influence of reproductive hor-
mones, studies on endocrine therapy for CMT are rare.
Gene or protein expression of ERα (ESR1) and/or ERβ
(ESR2), PGR, PRLR and GHR were detected in CMTs,
and decreased receptor expression was associated with
malignancy and/or a worse prognosis [8, 16, 24–32].
Nevertheless, the application of a PGR blocker decreased
PGR expression in canine mammary carcinoma cells and
reduced cell proliferation in vivo and cell viability in
vitro [33, 34]. The selective ER modulator tamoxifen,
which is part of the standard therapy for women with
ER-positive breast cancer [35–37], is not recommended
in dogs due to its partial agonistic potential and the
associated side effects [38, 39]. Lowering PRL serum
levels by oral application of the dopamine receptor agonist
cabergoline reduced the size of certain mammary lesions
in 25 % of clinically pseudopregnant dogs presenting with
mammary tumors [40].
Markers of tumor invasion are used in human medicine
to estimate survival time and prognosis [41]. E-cadherin,
the product of the CDH-1 gene, is expressed on the
surface of most epithelial cells and regulates cell-cell
adhesion. In women, loss or down-regulation of CDH-1 in
breast carcinoma is associated with shorter survival time
[42–44]. Similarly, in dogs, reduced immunostaining for
CDH-1 is correlated with increased invasion potential,
lymph node metastasis, histological grade and infiltration
[45–48].
Mastectomy is regarded as the most effective treatment
for CMT so far. However, further therapeutic options
should be sought, which could be used in combination
with surgery or in cases of non-operable lesions and
inflammatory mammary carcinomas. Knowledge of the
interplay between hormones and their receptors during
the reproductive cycle, after spaying or during tumorigen-
esis, could provide a basis for new and advanced thera-
peutic approaches for dogs with CMT.
Up to now, there is no information on the effect of
serum steroid hormone and PRL levels on their respective
receptor gene expression in normal and neoplastic mam-
mary tissues in dogs. Our goal was, therefore, to study the
associations between circulating serum concentrations of
E2, P4 and PRL, and the expression of genes encoding for
their respective receptors, i.e., ERα (ESR1), ERβ (ESR2),
PGR, PRLR, PRL, as well as GHR, in normal mammary
tissues as well as in mammary neoplasms in female dogs,
taking into account their reproductive state and cycle
stage. Furthermore, gene expression of CDH-1 was ana-
lyzed as a marker for tumor invasiveness in mammary tis-
sues showing different degrees of malignancy. In addition,
the influence of reproductive state and cycle stages were
assessed for all parameters.
Methods
Animals, tissues
A prospective study was carried out with 32 privately
owned female dogs that were presented with mammary
neoplasms to the Clinic of Reproductive Medicine,
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Vetsuisse Faculty in Zurich between 2009 and 2013.
Altogether, 56 mammary neoplasms and 28 normal mam-
mary tissue samples were collected from these patients.
Eleven dogs had only one mammary neoplasm and 21
bitches had two or more lesions. Mastectomy was
performed in 28 dogs to remove the masses. The follow-
ing surgery techniques were used: unilateral mastectomy
(n = 12), unilateral mastectomy combined with regional
mastectomy (n = 3), regional mastectomy (n = 11), exci-
sional biopsy (n = 2). Three of four dogs with inoperable
cancer were euthanized at initial presentation because of
their poor general condition. The fourth dog was eutha-
nized two months later because of severe dyspnea due to
pulmonary metastasis.
The phase of the estrous cycle at presentation was
determined based on history, clinical examination and
blood hormone assays (P4 and E2).
All owners consented to their animal becoming a
research participant and animal experimentation was ap-
proved by the Cantonal Veterinary Authority in Zurich,
Switzerland (permission No. 136/2009 and 165/2012).
Blood sampling and hormone analysis
In order to account for the possible pulsatile release and
circadian rhythm of PRL secretion [49, 50], two blood
samples were collected 30 min apart and always in the
morning from each dog prior to surgery or before
euthanasia. Samples were centrifuged after clotting, and
serum was stored at −20 °C until hormone analysis.
Serum PRL concentrations were measured with a previ-
ously validated heterologous radioimmunoassay (RIA) [51].
The intra-assay coefficient of variation was 3.5 %, and the
lower limit of detection was 0.8 ng/ml. All serum samples
were analyzed in the same run. The mean of the two PRL
concentrations from each dog was used for statistical
analysis.
E2 and P4 were determined from the first serum
sample. E2 concentrations were determined by a solid-
phase 125I-RIA (Count-A-Count TKE; Siemens Medical
Solution Diagnostics, Los Angeles, CA, USA) according to
the manufacturer’s instructions, with slight modifications as
described previously and validated for the dog [52, 53]. The
intra-assay coefficient of variation was 14 %, and the lower
limit of detection was 1.9 pg/ml. Serum P4 concentrations
were measured with a previously validated 3H-RIA [51, 54].
The intra- and inter-assay coefficients of variation were 11
and 9.7 %, respectively, and the lower limit of detection was
0.04 ng/ml.
Tissue collection, histopathological classification and
sample processing
Neoplastic and normal mammary tissue samples from
each dog were collected by surgical mastectomy, biopsy or
immediately post mortem. Tissue samples were fixed in
10 % buffered formalin for 24 h and embedded in paraffin.
Sections from each block were stained with hematoxylin
and eosin (HE) for histopathological diagnosis according
to the criteria of Goldschmidt [55], and then grouped as
normal mammary tissue, or benign or malignant mam-
mary neoplasms.
The experimental procedure was based on our previ-
ously established protocol [25]. Thus, on the HE stained
slides, representative parts of mammary neoplasms and
normal mammary tissue from each dog were identified
and marked. These parts were identified in the original
paraffin blocks, cut out manually and re-embedded sep-
arately in paraffin. Consecutive sections from these new
paraffin blocks were cut using a rotary microtome (RM
2165, Leica, Wetzlar, Germany). The first section (3 μm
thick) was used for control HE staining, the following
sections (10 μm thick) for RNA extraction (see below),
and the last section (3 μm thick) for another control HE
staining. The number of sections cut for RNA extraction
varied from 15 to 30 depending on neoplasm size. The
first and last control HE sections were compared to the
selected representative part of the mammary tissue
sample. If the control slides did not match the selected
tissue, the original paraffin block was re-sampled and re-
embedded as described above until both control slides
matched the selected area.
RNA extraction and semi-quantitative real-time (TaqMan)
PCR
Excess paraffin was manually removed from each repre-
sentative tissue section in a warm water bath (37 °C), and
all sections were transferred into a 1.5 ml plastic
Eppendorf tube (Eppendorf, Hamburg, Germany). Total
RNA was extracted using the RNeasy FFPE Kit (Qiagen,
Hombrechtikon, Switzerland) according to the manufac-
turer’s instructions. The RNA concentration was measured
with a NanoDrop 2000 UV–Vis Spectrophotometer
(Thermo Scientific, Wilmington, DE, USA). The RNA qual-
ity was assessed by checking the RNA integrity numbers
(RIN) and samples with similar RIN were used for all
groups. Extracted RNA was stored at −80 °C until analysis.
In order to remove genomic DNA contamination,
50 ng RNA per reaction was DNAse treated (RQ1
RNase-free DNase, Promega, Dübendorf, Switzerland) in
accordance with the manufacturer’s instructions. After-
wards, RNA was reverse transcribed into complementary
DNA (cDNA) using Sensiscript ™ Reverse Transcriptase
(Qiagen) and random hexamers (Applied Biosystems,
Foster City, CA, USA) as primers according to the man-
ufacturer’s instructions. All reactions were carried out in
an Eppendorf Mastercycler (Vaudaux-Eppendorf AG,
Basel, Switzerland).
Semi-quantitative real-time (TaqMan) PCR reactions for
ERα (ESR1), ERβ (ESR2), PGR, PRL, PRLR, GHR and
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CDH-1 were performed as described previously [56, 57]
using three independent endogenous reference genes
(canine GAPDH, 18SrRNA and cyclophilin A) in the
comparative CT method (ΔΔCT method). Samples were
run in duplicates on a 96-well optical plate using an
automated fluorometer ABI 7500 Fast Real Time PCR
System (Applied Biosystems). Per reaction, 6.25 μl Fast
Start Universal Probe Master (ROX) (Roche Diagnostics,
Rotkreuz, Switzerland), 300 nM of each primer, 200 nM
TaqMan probe, 1.75 μl autoclaved water, and 2.5 μl of
50 ng RNA were used as the TaqMan PCR reaction
mixture. Amplification was performed by denaturation for
10 min at 95 °C, 40 cycles at 95 °C for 15 sec and 60 sec at
60 °C. Autoclaved water and the RT minus control were
used as negative controls. The sequences of the primers
and the 6-carboxyfluorescein (6-FAM) and 6-carboxytetra
methyl-rhodamine (TAMRA) labeled TaqMan probes
were designed using Primer Express Software (Version
2.0, Applied Biosystems) and are listed in Table 1. All
primers and probes were purchased from Microsynth
(Microsynth AG, Balgach, Switzerland). The canine–spe-
cific TaqMan Gene Expression Assay of Cyclophilin A
(Prod. No. Cf03986523-gH), GHR (Prod No. Cf026234
59_m1) and CDH-1 (Prod. No. Cf02624268_m1) were
purchased from Applied Biosystems. The specificity of
selected PCR products for each gene was confirmed by
commercial sequencing (Microsynth).
Statistical analysis
Raw data are presented as the mean and standard devi-
ation (SD). A t-test was performed to compare serum
hormone levels of dogs in different reproductive states
and cycle stages. The statistical software “R” version
3.0.2 [58] and the package “nlme” [59] were used for the
analysis of different statistical models with receptor gene
expression as the outcome variable. Due to the repeated
measurements per animal, linear mixed-effects models
were applied. Animal was taken as a random effect. For
the analysis of receptor gene expression in mammary
tissue, outcome variables of PRLR, PGR, ERα (ESR1)
and ERβ (ESR2) were used with the following predictor
variables in the models: corresponding hormones of
PRL, P4, E2; tissue group with the categories normal,
benign, malignant; reproductive state and/or cycle with
the categories spayed, anestrous, diestrous. Additionally,
interactions between tissue group and hormone levels
were evaluated. For the outcome variables GHR and
CDH-1, the following predictor variables were tested:
tissue group (normal, benign, malignant), reproductive
state and/or cycle stage (spayed, anestrous, diestrous).
Table 1 List of primers and TaqMan probes used for the semi-quantitative real-time (TaqMan) PCR
Primer Accession number Primer sequence Product length (bp)
ERα (ESR1) XM533454 Forward: 5’-CCC ATG GAG GAG ACA AAC CA-3’, 93
Reverse: 5’-CCC TGC CTC CTC GGT GAT ATA-3’
TaqMan probe: 5’-CAC GGG CCC AAC TTC ATC ACA TTC-3’
ERβ (ESR2) XM861041 Forward: 5’-CCC AGC ACG CCC TTC A-3’ 78
Reverse: 5’-AAT CAT ATG CAC GAG TTC CTT GTC-3’
TaqMan probe: 5’-CCT CCA TGA TGA TGT CCC TGA CC-3’
GAPDH AB028142 Forward: 5’-GCT GCC AAA TAT GAC GAC ATC-3’ 75
Reverse: 5’-GTA GCC CAG GAT GCC TTT GAG-3’
TaqMan probe: 5’-TCC CTC CGA TGC CTG CTT CAC TAC CTT-3’
PGR NM_001003074 Forward: 5’-CGA GTC ATT ACC TCA GAA GAT TTG TTT-3’ 113
Reverse: 5’-CTT CCA TTG CCC TTT TAA AGA AGA-3’
TaqMan probe: 5’-AAG CAT CAG GCT GTC ATT ATG GTG TCC TAA CTT-3’
PRL NM_00108275 Forward: 5’-CAA GCC CAA CAG ATC CAC CAT-3’ 104
Reverse: 5’-ATC CCC CGC ACT TCT GTG A-3’
TaqMan probe: 5’-CTG AGG GTG CTG CGC TCC TGG-3’
PRLR HQ267784 Forward: 5’-GGA TCT TTG TTG CCG TTC TTT -3’ 92
Reverse: 5’-AAG GAT GCA GGT CAC CAT GCT AT-3’
TaqMan probe: 5’-ATT ATG GTC GTA GCA GTG GCT TTG AAA GGC-3’
18SrRNA FJ797658 Forward: 5’-GTC GCT CGC TCC TCT CCT ACT-3’ 125
Reverse: 5’-GGC TGA CCG CCT TGG TTT-3’
TaqMan probe: 5’-ACA TGC CGA CGG GCG CTG AC-3’
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For GHR and CDH-1, interactions between tissue group
and reproductive state and/or cycle stage were also
analyzed. Model selection was based on the Akaike
information criterion (AIC) with lower values indicating
a better model fit. A difference of at least −2 was consid-
ered as indicative of a better model fit. If AIC values
differed by less than 2, the model with the lowest num-
ber of predictors was chosen (principle of parsimony).
Results of the linear mixed effect models are given as
p-values and effect size with their standard errors (SE).
A p < 0.05 was considered significant.
Results
Animals and neoplasm classification
The ages of dogs at the time of blood and tissue sampling
ranged from 4.6 to 16.4 years (mean ± SD, 9.8 ± 2.69).
Bitches were of different breeds, the most frequent being
mixed breed dogs (n = 9), Jack Russell terriers (n = 3),
Boxers (n = 2) and dachshunds (n = 2).
Twenty-four bitches were intact, of which 13 were in
anestrus and 11 in diestrus. Eight dogs had been previously
spayed before the time of mastectomy, six between the ages
of 7 and 10 years, one before 18 months of age, and in one
dog no information was available.
The group of benign mammary neoplasms consisted of
19 tissue samples out of 12 dogs, the malignant neoplasia
group of 37 samples from 24 dogs. Benign neoplasms
included complex adenomas (n = 10), simple adenomas
(n = 6), mixed benign mammary tumors (n = 2) and one
ductal adenoma. The malignant group consisted of
complex carcinomas (n = 14), simple carcinomas (n = 12),
anaplastic carcinomas (n = 3), solid carcinomas (n = 3),
ductal carcinomas (n = 3), one adeno-squamous carcin-
oma, and one carcinoma and malignant myoepithelioma.
Normal tissue was available from 28 dogs.
Hormonal analysis and gene expression
Serum levels of E2, P4 and PRL varied between 0.52 and
16.32 pg/ml, 0.05 and 91.4 ng/ml, and 1.32 and 8.91 ng/
ml, respectively (Table 2). Serum for E2 measurement
was not available from two dogs that were both affected
by simple adenomas.
Gene expression of ERα (ESR1), PGR, PRLR, GHR and
CDH-1 was detected in normal mammary tissues and in
all mammary neoplasms, except in one carcinoma. The
PRL and ERβ (ESR2) mRNA expression was below the
detection limit in most of the samples in all groups,
revealing more negative than positive results and, thereby,
indicating their low expression levels. Corpus luteum
tissue (mid-diestrus) used as a positive control tested
positively for both factors (Additional file 1 (1.2)).
Regarding gene expression of reproductive hormone
receptors, the best predictor variable tested was “tissue
group” for ERα (ESR1) (p = 0.03), PGR (p = 0.008) and
PRLR (p = 0.001). Thus, malignant tumors showed signifi-
cantly lower ERα (ESR1) and PGR gene expression than
normal mammary tissues (p = 0.017 and p = 0.002,
respectively; Fig. 1A and B). PRLR mRNA expression was
significantly lower in both benign and malignant mam-
mary neoplasms than in normal tissues (p = 0.009 and
p < 0.001, respectively) with lowest values detected in
the malignant group (Fig. 1C).
Out of the models containing “hormone blood level”
and “tissue group” a relationship was only found for PRLR
mRNA expression: PRL blood levels had a negative rela-
tionship with PRLR gene expression only in malignant
neoplasms (p = 0.025). In contrast to these finding, the
corresponding models for PGR and ERα (ESR1) did not
show a relationship with their hormone levels (p = 0.07
and p = 0.11, respectively).
GHR gene expression was also predicted best by “tissue
group” (p = 0.008). Consequently, GHR mRNA levels were
significantly lower in malignant neoplasms compared to
normal mammary tissue (p = 0.003; Fig. 1D).
In all other models, i.e., those using the predictors
variable blood level, reproductive state and/or cycle stage,
as well as the interaction between tissue group and repro-
ductive state/cycle stage variables, were not significantly
associated with receptor expression.
In contrast to the expressions of reproductive hormone
receptors, the gene expression for CDH-1 revealed a signifi-
cant interaction (p = 0.012) for both “tissue group and
reproductive state and/or cycle stage”. Among diestrous
bitches, CDH-1 gene expression was highest in benign
neoplasms compared to normal mammary tissue and
malignant neoplasms (p = 0.001 and p = 0.008, respectively;
Fig. 1E). However, no such differences were found between
samples collected in other reproductive states or cycle
stages, either in spayed animals (p = 0.63 and p = 0.89,
respectively) or in anestrous dogs (p = 0.09 and p = 0.09,
respectively). Analyzing mammary samples according to
“tissue group”, benign neoplasms from diestrous bitches
expressed significantly higher levels of CDH-1 mRNA than
benign neoplasms from spayed or anestrous dogs (p = 0.003
Table 2 Serum E2, P4 and PRL concentrations in dogs with
mammary neoplasms
E2 (pg/ml) P4 (ng/ml) PRL (ng/ml)
all dogs (n = 32) 7.85 ± 4.70 9.57 ± 21.50 3.97 ± 1.92
spayed (n = 8) 2.35 ± 1.12a 0.30 ± 0.27 2.97 ± 1.16b
intact (n = 24) 9.85 ± 3.79a 12.67 ± 24.14 4.31 ± 2.02b
anestrous (n = 13) 8.09 ± 4.08c 0.47 ± 0.40d 3.99 ± 2.13
diestrous (n = 11) 11.95 ± 2.05c 27.08 ± 30.31d 4.69 ± 1.90
Values are shown as mean ± SD. Same superscripts within a column denote
significant differences at p < 0.05 (assessed with a t-test).
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and p = 0.026, respectively; Fig. 1F). CDH-1 gene expression
in malignant neoplasms and in normal mammary tissue
was similar between diestrous and spayed (p ≥ 0.23), and
between diestrous and anestrous dogs (p ≥ 0.33). The AIC
values of models, which tested the relationship between the
expression of CDH-1 and E2, P4, or PRL levels were higher
than those determined for the model describing the expres-
sion of CDH-1 gene in dependence of tissue group and
Fig. 1 Model results of relative gene expression (fold changes in mRNA levels, mean ± SE) of A ERα (ESR1), B PGR, C PRLR and D GHR in normal
mammary tissue, benign and malignant neoplasms. The significant interaction for tissue group and reproductive state/cycle on CDH-1 gene
expression is shown in (E,F); E Relative gene expression (RGE; fold changes in mRNA levels, mean ± SE) of CDH-1 in normal mammary tissue, be-
nign and malignant mammary neoplasms of diestrous dogs; F Relative gene expression (RGE; fold changes in mRNA levels, mean ± SE) of CDH-1
in benign mammary neoplasms collected from spayed dogs, anestrous and diestrous bitches. Bars with different superscripts differ at p < 0.05
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reproductive status/cycle stage. Thus, hormone levels had
no influence on CDH-1 expression in our study.
Detailed information on hormone levels, reproductive
states and cycle stages, and relative gene expression of re-
ceptors detected in normal tissues and/or mammary tu-
mors per dog are presented in the Additional file 1 (1.1).
Discussion
Growth of mammary epithelial cells is stimulated by steroid
hormones [60, 61], PRL [62] and GH [7]. In dogs, most
studies showed lower ERα (ESR1) as well as PGR expres-
sion in malignant compared to benign mammary tumors
[29, 31, 63] or normal mammary tissue [16, 30, 29]. A
tendency for decreased GHR expression was also noted,
particularly in undifferentiated carcinomas [7, 8], which
showed heterogeneous immunoreactivity compared to
diffuse staining in normal tissue and benign tumors [8].
These studies are in accordance with our findings of
decreased mRNA expression of ERα (ESR1) and PGR in
malignant CMTs compared to normal tissue, although
benign neoplasms were not different in these respects from
either malignant or normal samples. The loss of or
decreased receptor expression may be indicative of increas-
ing resistance to hormonal stimulatory effects [64], and
might serve as an indicator of malignancy as suggested
before [8, 16, 29–31, 63].
The possible influence of steroid hormone levels on
mammary tumors in dogs was previously investigated
[16–18]. Thus, higher E2 concentrations were found
both in serum as well as in tissue homogenates in cases
of non-inflammatory malignant neoplasms compared to
normal mammary tissue [16–18] or to benign tumors
[17]. P4 levels showed a similar trend but only in tissue
homogenates [18]. In contrast to these previous studies,
which included only intact dogs in anestrus [16–18], our
animal population represented different reproductive
states and cycle stages including diestrous dogs, and
various types of mammary tissue samples to take into
account the multicentric nature and diversity of CMTs
[65]. This approach may include possible effects of a
malignant neoplasm on the remaining mammary gland,
i.e., altering its gene expression levels or influencing sex
steroid and PRL serum levels. However, to gather suffi-
cient information, a much larger data base would be
required. Furthermore, to investigate the postulated
tumor-promoting effects of sex hormones during early
carcinogenesis, longitudinal data would be desirable.
All of the above-cited studies evaluated either expres-
sion patterns of the respective hormone receptors, or
the hormonal status of diseased dogs, and/or the local
hormonal status of tumors. However, the association
between these entities within one animal population has
never been studied before. Consequently, the present
study was initiated to establish such possible
relationships. Based on the results presented herein, we
infer that neoplasm type is the primary determinant of ca-
nine mammary steroid hormone receptor gene expression
while other factors, including circulating steroid hormone
serum concentrations, reproductive state and cycle stage,
as well as interactions among the above, seem to have
little or no influence. This is not surprising, because most
dogs affected by mammary cancer have multiple lesions of
different histological types [55, 66, 67]. Therefore, we
intentionally included more than one neoplasm per dog
when several lesions were present, and took the animal as
a random factor into account in the statistical analyses as
this best represented the affected dog population.
Considering the lack of the effect of the reproductive
status and/or cycle stage, and thereby, of the hormonal
status on the respective hormone receptor expression, this
could be due to the physiological high variation of hormo-
nal levels in dogs, overlapping with the limited number of
samples used for our study, and the possible breed effects.
The PRL-PRLR complex plays a role in mammary
tumorigenesis, as shown, e.g., in human breast cancer
[68]. In agreement with our previous study [25], we
detected decreasing PRLR gene expression levels during
the course of malignant transformation, i.e., from
normal mammary tissue towards benign and further to
malignant transformation [25]. However, in that previous
study, the reproductive state of the dogs was unknown,
serum hormone levels were not investigated and CMTs
consisted of a more homogeneous group of adenomas
and adenocarcinomas. In the present study, we found
increased serum PRL levels in malignant CMTs, which
were associated with low PRLR gene expression.
Similarly, high PRL concentrations in serum and tissue
homogenates were previously shown in dogs suffering
from malignant tumors [17, 23]. One possible explan-
ation for these findings is that high levels of PRL
induced down-regulation of PRLR transcription in the
mammary gland. This could be a sign of loss of differen-
tiation in the neoplastic cells, in which case PRL would
have little or no effect in these malignant neoplasms.
PRL is known to modulate the availability of its own
receptor by stimulating its proteolytic degradation. This
impaired PRLR turnover, which leads to its stabilization
and accumulation, presumably increases the magnitude
and duration of PRL signaling and contributes to trans-
formation of human mammary epithelial cells [69, 70].
As indicated above, in dogs as in humans, PRL can be
produced not only in the anterior pituitary, but also in
normal mammary tissue and malignant mammary tumors
[17, 23, 71–73]. Moreover, higher tissue PRL levels were
observed by Queiroga and colleagues in CMT homogenates
[17, 23]. Consequently, the autocrine/paracrine loop of
mammary PRL-PRLR complex [71–73] contributing to hu-
man breast cancer development [74] has also been implied
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for the dog [17, 75]. Contrasting with these previous find-
ings, in the present study the local expression of PRL
mRNA was below detection limits in the canine mammary
gland. However, mRNA concentrations might not always
reflect the actual PRL concentrations at the protein level.
The activation of PRLR by PRL results in signaling
through the Jak2/Stat5a pathway. Stat5 activation initiates
cell differentiation through expression of the CDH-1-
β-catenin complex [76, 77], which may suggest a protect-
ive effect of PRL against neoplasm formation, because
decreased Stat5a activation was associated with metastatic
progression in human breast cancer [78]. At present, it is
still not clear whether PRL acts as a promoter or a
suppressor of neoplasm development or as a promoter of
differentiation [79–82]. Nevertheless, reduced immuno-
histochemical expression of CDH-1 in the mammary
gland was related to malignancy, invasive growth, lymph
node metastasis, necrosis, differentiation grade, size and
ulceration of the tumor in dogs [45–48, 83]. There is
limited knowledge on the molecular mechanisms behind
CDH-1 down-regulation in CMTs, and about when it
occurs during neoplastic progression. Pardini and
colleagues [84] showed decreased CDH-1 mRNA expres-
sion in dogs with mammary carcinoma compared to nor-
mal tissue. We could not confirm this finding, as in our
study similar mRNA concentrations were detected in nor-
mal mammary tissue and in malignant neoplasms. How-
ever, modifications in post-translational N-glycosylation of
CDH-1 [85] cannot be ruled out, which may result in
decreased cell-cell adhesion in the malignant lesions.
Interestingly, we found increased CDH-1 gene expression
in benign compared to malignant neoplasms, which
supports the role of CDH-1 as a marker for cell differenti-
ation. This is in line with the lack of metastatic and inva-
sive properties of benign neoplasms. The highest CDH-1
mRNA levels were seen in benign lesions during the dies-
trus phase, which may be attributed to the effects of P4.
Similarly, CDH-1 gene expression was up-regulated in the
canine uterus under P4 treatment and during pregnancy
[86]. In contrast to our expectations, reproductive state or
cycle stage had no effect on CDH-1 mRNA levels in
normal mammary tissue. This could be, however, due to
the source of the normal/healthy tissue used for the
present study, which was collected from dogs affected by
mammary tumors. The microenvironment of malignant
mammary tumor could have a modulatory effect on the
expression of CHD-1.
Conclusion
The transformation from a normal to a malignant
phenotype was associated with a significant loss of ERα
(ESR1), PGR, GHR and PRLR gene expression in the
mammary tissue of dogs. Only PRLR gene expression was
significantly decreased concurrently with the formation of
benign tumors. Increased levels of serum PRL, but not of
P4 and E2, were associated with a decrease in gene expres-
sion of the respective receptors only in malignant mam-
mary neoplasms. No evidence was found for the presence
of a paracrine/autocrine action of PRL in the canine
mammary gland. CDH-1 mRNA expression was higher in
benign compared to malignant neoplasms and normal
mammary tissue and thus may serve as a prognostic
marker.
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